Search results
Jump to navigation
Jump to search
- ...describing the relationship between an in-vitro property of a dosage form and an in-vivo response". ...parameter derived from a biological property produced from a dosage form, and a physicochemical property of the same dosage form". ...3 KB (438 words) - 10:46, 10 April 2021
- ...nter for Veterinary Medicine]] of the US [[Food and Drug Administration]], and chaired the Biopharmaceutical Section of the [[American Statistical Associa ==Early life and education== ...4 KB (631 words) - 10:32, 7 April 2024
- ...y considered to have no detectable effects. Currently the [[Food and Drug Administration|FDA]] stipulates that diagnostic ultrasound scanners cannot exceed a mechan ...2 KB (237 words) - 20:14, 19 January 2024
- | workplaces = [[Food and Drug Administration]]<br>[[National Institutes of Health]] ..., ''Statistical Hypothesis Testing in Context: Reproducibility, Inference, and Science'' (with Michael P. Fay, Cambridge University Press, 2022). ...4 KB (491 words) - 04:06, 14 August 2024
- ...o administration, the iron deficiency should be diagnostically established and verified via laboratory tests (e.g., low [[ferritin]] concentration, low [[ The drug has been on the market since 1978 and is approved in over 85 countries. In many countries it is known with brand ...11 KB (1,447 words) - 04:44, 5 July 2024
- ...Observed Effect Concentration ([[No-observed-adverse-effect level|NOEC]]) and the lowest observed effect concentration ([[Lowest-observed-adverse-effect ...ection Agency]] (US EPA) and other organizations to maintain high accuracy and precision among all toxicity tests for regulatory purposes. ...9 KB (1,424 words) - 21:45, 27 November 2024
- | birth_date = {{birth date and age|1950|9|16}} ...e [[Chronic Kidney Disease]] and apply them in clinical practice, research and public health. ...14 KB (1,853 words) - 00:28, 6 January 2024
- {{Short description|Integral of drug concentration in blood plasma over time}} ...der the curve” or AUC) gives insight into the extent of exposure to a drug and its [[Clearance rate (biochemistry)|clearance rate]] from the body.<ref>{{C ...11 KB (1,446 words) - 09:43, 18 August 2023
- ...xicology, there are some other safety factors including [[LD50]], [[LC50]] and [[EC50]]. ...pharmaceuticals |publisher=National Centre for the Replacement, Refinement and Reduction of Animals in Research|year=2009|location=London|pages=21}}</ref> ...23 KB (3,276 words) - 13:09, 13 January 2025
- {{Food safety}} {{about|food science|a more general discussion|thermodynamic activity}} ...22 KB (3,163 words) - 09:58, 28 February 2025
- ...as a fat replacer in food.<ref name=":0">{{Cite book|title=Emulsifiers in Food Technology|url=https://archive.org/details/emulsifiersfoodt00whit|url-acces ...-10-19}}</ref> In 1921, Hess and Messner synthesized sucrose octapalmitate and sucrose octastearate. Both are sucrose fatty acid esters. ...26 KB (3,905 words) - 07:56, 22 January 2025
- ...eam and cheese.jpg|thumb|Bowl of [[Chili con carne|chili]] with sour cream and cheese]] ...our cream and chili sauce.jpg|thumb|Crisp [[potato]] skins with sour cream and chili sauce]] ...21 KB (3,037 words) - 00:01, 19 February 2025
- ...u|first8=Qing-Rong|date=October 2008|title=Molecular Genetics of Addiction and Related Heritable Phenotypes|journal=Annals of the New York Academy of Scie ...craving |year=2002 |last1=Franken |first1=Ingmar H.A. |journal=Personality and Individual Differences |volume=32 |issue=2 |pages=349–355}}</ref> ...32 KB (4,506 words) - 09:34, 6 October 2024
- ...er a drug or nutrient is infused or ingested at a relatively constant rate and when a constant fraction is eliminated during each time interval. Under the ...of Body Constituents. Harvard University Press, Cambridge, MA, 1942.</ref> and [[David Rittenberg]].<ref>{{Cite journal |doi=10.1016/s0021-9258(18)71388-4 ...27 KB (4,013 words) - 09:11, 31 August 2024
- ...was the first β<sub>3</sub>-AR agonist to be approved in the United States and Europe for the treatment of overactive bladder (OAB) syndrome.<ref name=":0 ...ug Administration]] (FDA) as a medicine. The medicine is called Mirabegron and is used to treat OAB.<ref name=":0">{{Cite web|url=https://www.ema.europa.e ...21 KB (3,136 words) - 17:52, 12 October 2024
- ...move quickly through substances, like water or blood, efficiently finding and attacking unwanted matter. Nanosponges are often synthetically manufactured ...lli|first3=Roberta|date=2012-11-29|title=Cyclodextrin-based nanosponges as drug carriers|journal=Beilstein Journal of Organic Chemistry|language=en|volume= ...38 KB (5,550 words) - 11:13, 1 February 2023
- ...structive [[tissue engineering]] as scaffolding, as well as use in passive and preventive applications. ...the selected solvent system. The following sections summarize the chemical and physical methods by which hydrogels are crosslinked.<ref name="Novel Crossl ...34 KB (4,801 words) - 12:27, 29 June 2024
- ...d Cardiotoxicity |journal=International Journal of Pharmaceutical Sciences and Research |year=2018 |volume=9 |issue=1 |pages=16–26 |doi=10.13040/IJPSR.097 ...|last2=Kim* |first2=Sung-Jin |year=2016 |title=Pharmacological Activities and Applications of Spicatoside A |journal=Biomolecules & Therapeutics |volume= ...31 KB (4,064 words) - 12:51, 24 January 2025
- ...(journal)|Jurimetrics]]'' is published by the [[American Bar Association]] and [[Arizona State University]].<ref>{{Cite web|url=http://www.americanbar.org ...ell Holmes Jr.]], Loevinger quoted<ref>Loevinger, L. "Jurimetrics: Science and prediction in the field of law". ''[[Minnesota Law Review]]'', vol. 46, Hei ...36 KB (4,940 words) - 10:47, 9 February 2025
- ...n the [[central nervous system]], [[Autonomic ganglion|autonomic ganglia]] and [[neuromuscular junction]]s, which are rich in [[acetylcholine receptor]]s. ...ndžić AM, Vasić VM | title = Acetylcholinesterase inhibitors: pharmacology and toxicology | journal = Current Neuropharmacology | volume = 11 | issue = 3 ...26 KB (3,189 words) - 20:48, 27 January 2025